Getting to work on pipeline construction, new Ipsen CEO forges $1B deal to buy Merrimack’s struggling Onivyde
Merrimack Pharmaceuticals and Ipsen, two biotechs looking to reorganize and move up in the world, have struck a billion-dollar deal for a floundering cancer therapy. The Paris-based Ipsen is handing over $575 million in cash and promising up to $450 million in milestones to grab Merrimack’s US rights to Onivyde, approved for pancreatic cancer. And new Ipsen CEO David Meek tells Endpoints that you can expect more deals to come.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.